[Proliferative retinal vasculitis and multiple sclerosis: a case report].
BACKGROUND
Retinal periphlebitis can precede the neurological effects of multiple sclerosis and reveal the disease. Although these occurrences of vasculitis are noted in 10% - 35% of multiple sclerosis patients, proliferative retinopathy is, on the contrary, an exceptional complication.


METHODS
We report the case of a 28-year-old woman who presented bilateral, proliferative, retinal vasculitis complicated with recurrent vitreous hemorrhages occurring with multiple sclerosis. Initially, there was a unilateral, central venous thrombosis in a particularly ischemic and proliferative form. After a neurological, biological and radiological check-up, the diagnosis of multiple sclerosis was pronounced and treatment with Interferon was started. A pan-retinal laser photocoagulation and vitrectomy with proliferative membrane peeling were performed. After a follow-up of 2.5 years, a bilateral epiretinal membrane on the macula with a chronic macular edema persisted, with visual acuity limited to 0.2 Parinaud 4 in the right eye and 0.5 Parinaud 2 in the left eye.


CONCLUSIONS
This case shows that the diagnosis of multiple sclerosis must be established in cases of ischemic retinal vasculitis, especially as the literature does not seem to report a correlation between the retinal vascular affect and how far multiple sclerosis has progressed. Moreover, the visual prognosis of these proliferative lesions remains uncertain.


CONCLUSIONS
Multiple sclerosis can be revealed initially, although exceptionally, by bilateral, proliferative and severe retinal vasculitis complicated with recurrent vitreous hemorrhages and tractional retinal detachment.
Patte
M
M
Service d'Ophtalmologie.
Rouher
F N
FN
Vernay
D
D
Delaire
J-C
JC
Bacin
F
F
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001327:Autoimmune Diseases / Q000150:complications* / Q000188:drug therapy; D003131:Combined Modality Therapy; D017679:Cryotherapy; D018450:Disease Progression; D019773:Epiretinal Membrane / Q000209:etiology; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008028:Light Coagulation; D008269:Macular Edema / Q000209:etiology; D009103:Multiple Sclerosis / Q000150:complications* / Q000188:drug therapy; D018917:Optic Neuropathy, Ischemic / Q000209:etiology*; D031300:Retinal Vasculitis / Q000188:drug therapy / Q000209:etiology*; D012170:Retinal Vein Occlusion / Q000209:etiology; D014792:Visual Acuity; D014821:Vitrectomy; D014823:Vitreous Hemorrhage / Q000209:etiology* / Q000601:surgery
D000305:Adrenal Cortex Hormones; D007372:Interferons